News

CCTV News reported ProteLight

2016-08-11

On August 9th, CCTV News reported Jiangyin Hi-Tech District and Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd., as a high technology and pharmaceutical corporation, ProteLight develops well in the industrial environment of Jiangyin High-Tech District.

   The first from the left is Dr. Yuxin Chen, Chairman of Placid, and the second from the left is Dr. Robert S. Hodges, Chief Scientific Officer of Placid 

The picture shows our company's QC testing products

The picture shows the production line of our company's "Oti antibacterial lotion"  

Previous article

ProteLight Signed at Jianying Economic and Trade Fair

Next article

Anti-infection 1.1 New Drug PL-5 is approved to be in Clinical Trial

/news_detail/49.html

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

—

2024-10-26

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-3301 Oral Gel Has Been Granted FDA Approval To Commence Clinical Trials.

■

The publication of a confirmative Phase III clinical study on Peceleganan Spray (project code: PL-5), an innovative antimicrobial peptide developed by ProteLight Pharms, has been released.

■

ProteLight Pharma was selected into the list of “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023”

■

Congratulations to the company for passing the ISO9001 quality management system certification

■

Antimicrobial Peptide PL-18 Suppository (First-in-class new drug) of ProteLight Pharma Received Clinical Trial Approval from CDE in China